Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Etoposide
Drug: Azacitidine
Drug: Lenograstim

First Posted Date: 2010-08-12

Last Posted Date: 2020-12-31

Lead Sponsor: University of Ulm

Target Recruit Count: 277

Registration Number: NCT01180322

Locations: 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇩🇪
Universitätsklinikum Schleswig-Holstein, Kiel, Germany
🇦🇹
Krankenhaus der Barmherzigen Schwestern, Linz, Austria

and more 40 locations

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: midostaurin
Drug: Bortezomib
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine

First Posted Date: 2010-08-04

Last Posted Date: 2016-07-06

Lead Sponsor: Alison Walker

Target Recruit Count: 34

Registration Number: NCT01174888

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Phase 1

Active, not recruiting

Conditions: Regional Neuroblastoma
Ganglioneuroblastoma
Localized Unresectable Neuroblastoma
Stage 4 Neuroblastoma
Localized Resectable Neuroblastoma
Stage 4S Neuroblastoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide Phosphate
Radiation: External Beam Radiation Therapy
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Intensity-Modulated Radiation Therapy
Radiation: Iobenguane I-131
Drug: Isotretinoin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Other: Pharmacological Study
Other: Questionnaire Administration
Procedure: Therapeutic Conventional Surgery
Drug: Topotecan Hydrochloride
Drug: Vincristine Sulfate

First Posted Date: 2010-08-04

Last Posted Date: 2025-01-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 99

Registration Number: NCT01175356

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 22 locations

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy

Phase 2

Conditions: Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

First Posted Date: 2010-07-30

Last Posted Date: 2013-08-12

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 47

Registration Number: NCT01172912

Locations: 🇮🇹
Fondazione Istituto Nazionale dei Tumori, Milan, Italy

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Panobinostat
Drug: Ifosfamide
Drug: Mesna
Drug: Carboplatin
Drug: Etoposide
Drug: Pegfilgrastim

First Posted Date: 2010-07-26

Last Posted Date: 2021-01-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT01169636

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Drug: Carboplatin
Biological: Rituximab
Drug: Etoposide
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-07-19

Last Posted Date: 2018-12-05

Lead Sponsor: University of Washington

Target Recruit Count: 48

Registration Number: NCT01165112

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: etoposide
Drug: everolimus
Drug: idarubicin
Drug: mitoxantrone hydrochloride

First Posted Date: 2010-06-30

Last Posted Date: 2022-10-26

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 11

Registration Number: NCT01154439

Locations: 🇮🇹
Università La Sapienza, Roma, Italy
🇮🇹
Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia, Napoli, Italy
🇮🇹
Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy

and more 2 locations

Autologous Transplant in HIV Patients (BMT CTN 0803)

Phase 2

Completed

Conditions: HIV
Lymphoma

Interventions: Procedure: Autologous transplant
Drug: BCNU
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan

First Posted Date: 2010-06-10

Last Posted Date: 2023-01-04

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 43

Registration Number: NCT01141712

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
University of CA, SF, San Francisco, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 13 locations

Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Vinblastine
Radiation: Radiation therapy

First Posted Date: 2010-06-02

Last Posted Date: 2015-03-27

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 610

Registration Number: NCT01134861

Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: bortezomib
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine
Other: flow cytometry

First Posted Date: 2010-05-20

Last Posted Date: 2015-08-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 3

Registration Number: NCT01127009

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy